Compare Aurora Cannabis Inc (ACB) vs Kinder Morgan Inc (KMI) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

KMI trades at $32.49, up 1.34% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and maintains a solid dividend of $0.30 per share. Revenue grew to $16.94B in 2025, with net income reaching $3.06B, reflecting an 18.04% margin. Analyst consensus is mixed, with 47% buy ratings and 50% hold.

KMI's outlook is supported by stable cash flows from fee-based contracts and a $10.1B project backlog focused on natural gas infrastructure. Key risks include high debt levels and exposure to energy market volatility. The stock offers income potential with a near 4% yield, but investors should monitor execution on growth projects and commodity price trends.